
Tuesday, February 27, 2018 12:09:29 AM
Question one was me again asking about the Patents on the USPTO website and when would they update to show back under Delcath control and no longer being held as a security interest by Hudson Bay?
Question two was regarding how as an accredited investor, I called my broker about the offering, but was not able to participate in the recent 250M share offering? My broker said they did not see a public offering open for Delcath? As typically there is an announcement about opening of a public offering, price per share of public offering, length of time for public offering, and date expected to close public offering...my brokerage had nothing for me and suggested it was a private placement.
DELCATH IR RESPONSE:
Thank you for your inquiry.
Regarding the status of the patents related to our 2016 Convertible Note, as we’ve stated previously the process for updating the relevant filings has been initiated and we do not know when the updates will be reflected in the UPTO database.
Regarding the recent equity raise, per our filings with the SEC related to this offering, Roth Capital Partners acted as sole agent for this placement. Please consult our filings available from http://delcath.com/sec-filings/ for additional information.
Please continue to monitor our public filings as they are made for additional information.
Regards,
Delcath Investor Relations
investorrelations@delcath.com
www.delcath.com
In My Own Personal Opinion Of Course!

Liked By
Spread the love. Be the first to like this post!
Recent DCTH News
- Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) • Edgar (US Regulatory) • 02/27/2023 10:00:16 PM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 02/24/2023 11:08:32 AM
- Delcath Announces Rotation of the Board of Directors Chairmanship; John R. Sylvester Appointed New Chairman as Company Prepares for US Commercial Launch • PR Newswire (US) • 02/16/2023 01:30:00 PM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 02/14/2023 03:59:47 PM
- Delcath Systems Announces New Drug Application Resubmission for HEPZATO Kit • PR Newswire (US) • 02/14/2023 01:49:00 PM
- Delcath Systems to Participate at the BTIG MedTech, Digital Health, Life Sciences & Diagnostic Tools Conference on February 14 to 16 • PR Newswire (US) • 01/30/2023 01:30:00 PM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 01/23/2023 12:01:47 PM
- Notice of Effectiveness (effect) • Edgar (US Regulatory) • 01/23/2023 11:04:04 AM
- Delcath Systems Announces Updated Results from CHOPIN Phase 1b Trial Published in Cardiovascular and Interventional Radiology • PR Newswire (US) • 01/17/2023 01:00:00 PM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 01/10/2023 09:13:57 PM
- Securities Registration Statement (simplified Form) (s-3) • Edgar (US Regulatory) • 01/10/2023 09:08:24 PM
- Amended Statement of Ownership (sc 13g/a) • Edgar (US Regulatory) • 12/29/2022 10:28:09 PM
- Tender Offer Statement by Issuer (sc To-i) • Edgar (US Regulatory) • 12/21/2022 05:18:41 PM
- Amended Statement of Beneficial Ownership (sc 13d/a) • Edgar (US Regulatory) • 12/16/2022 10:07:45 PM
- Delcath Systems Announces Inducement of Grant Under NASDAQ Listing Rule 5635(C)(4) • PR Newswire (US) • 12/16/2022 09:15:00 PM
- Small Company Offering and Sale of Securities Without Registration (d) • Edgar (US Regulatory) • 12/16/2022 08:04:28 PM
- Statement of Changes in Beneficial Ownership (4) • Edgar (US Regulatory) • 12/16/2022 02:32:48 PM
- Statement of Changes in Beneficial Ownership (4) • Edgar (US Regulatory) • 12/14/2022 09:55:08 PM
- Statement of Changes in Beneficial Ownership (4) • Edgar (US Regulatory) • 12/14/2022 09:43:16 PM
- Statement of Changes in Beneficial Ownership (4) • Edgar (US Regulatory) • 12/14/2022 08:35:42 PM
- Delcath Systems Closes Private Placement of $6.2 Million • PR Newswire (US) • 12/13/2022 01:30:00 PM
- Delcath Systems Announces Private Placement of $6.2 Million • PR Newswire (US) • 12/08/2022 01:30:00 PM
- Results of a Single Center Study on Delcath's CHEMOSAT® Hepatic Delivery System In the Treatment of Cholangiocarcinoma Published in the Journal Clinical & Experimental Metastasis • PR Newswire (US) • 12/05/2022 02:00:00 PM
- Delcath Systems (DCTH) Receives a Buy from H.C. Wainwright • TipRanks • 11/10/2022 11:35:43 AM
- Analysts Offer Insights on Healthcare Companies: Delcath Systems (DCTH), Curis (CRIS) and AquaBounty Technologies (AQB) • TipRanks • 11/10/2022 11:21:12 AM
Nextech3D.ai Announces Its AI-Powered SaaS Platform Toggle3D Experiences A +963% Jump in Users in 60-Days Crossing Over 1000 Users • NTAR • Mar 23, 2023 7:07 AM
Lifecycle Assessment by Benchmark Shows TMC's NORI-D Nodule Project Could Outperform Land-Based Routes of Producing Nickel, Copper and Cobalt in Almost Every Impact Category Analyzed • TMC • Mar 22, 2023 1:44 PM
Fineqia Announces Partnership with Paris Blockchain Week to Accelerate Digital Asset Innovation • FNQQF • Mar 22, 2023 10:03 AM
E-Cite and ClearMarket Launch Nationwide EV Distribution Network Becoming the First All EV Dealership Opening in the Cerritos Auto Square, the World's Largest Automall • VAPR • Mar 22, 2023 9:41 AM
Electromedical Announces $1.36M Net Proceeds from Building Sale to Fund WellnessPro Infinity ™ Launch and Convertible Note Retirement. • EMED • Mar 22, 2023 7:04 AM
HealthLynked Corp. Awarded Patent 11,600,395 for "Secure Patient Access via Healthcare Service Provider Specific Wireless Access Point" • HLYK • Mar 21, 2023 8:00 AM